Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Long-term therapy with spironolactone.

M L Bouvy1, E R Heerdink, R M Herings

  • 1Department of Pharmacoepidemiology & Pharmacotherapy, Faculty of Pharmacy, Utrecht University, The Netherlands. m.bouvy@pharm.uu.nl

Pharmacy World & Science : PWS
|October 16, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Blinded withdrawal of randomized treatment with low-dose digoxin or placebo in patients with heart failure: the DECISION trial.

European heart journal·2026
Same author

Low-dose digoxin in patients with heart failure with reduced or mildly reduced ejection fraction: a randomized controlled trial.

Nature medicine·2026
Same author

Fostering moral reflectivity in community pharmacists through moral case deliberation using the dilemma method.

International journal of clinical pharmacy·2025
Same author

General practitioners' and community pharmacists' beliefs and practices on opioids for non-malignant pain.

European journal of pain (London, England)·2024
Same author

Cognitive processes in pharmacists' clinical decision-making.

Research in social & administrative pharmacy : RSAP·2023
Same author

Factors influencing pharmacists' clinical decision making in pharmacy practice.

Research in social & administrative pharmacy : RSAP·2023
Same journal

In Memoriam.

Pharmacy world & science : PWS·2018
Same journal

UKCPA News.

Pharmacy world & science : PWS·2018
Same journal

Severe akathisia as a side effect of metoclopramide.

Pharmacy world & science : PWS·2010
Same journal

Introduction of pharmaceutical expertise in a palliative care team in Sweden.

Pharmacy world & science : PWS·2010
Same journal

Cost reduction associated with restriction policy on dispensing intravenous esomeprazole in Lebanon.

Pharmacy world & science : PWS·2010
Same journal

Azathioprine-induced severe cholestatic hepatitis in patient carrying TPMT*3C polymorphism.

Pharmacy world & science : PWS·2010
See all related articles

Spironolactone therapy discontinuation is common in heart failure patients, with over half stopping treatment. Maintaining combination therapy with ACE inhibitors also proves challenging for many patients.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Spironolactone is a medication used in heart failure management.
  • Understanding real-world adherence to spironolactone therapy is crucial.

Purpose of the Study:

  • To evaluate the duration of spironolactone therapy in routine clinical practice.
  • To assess the persistence of spironolactone use and combination therapy with ACE inhibitors.

Main Methods:

  • Retrospective cohort study of patients with heart failure (CHF) and a new spironolactone prescription.
  • Follow-up of patient therapy duration and discontinuation rates.

Main Results:

  • 58.8% of patients discontinued spironolactone, with 40.8% discontinuing within 6 months.
  • Concomitant use of spironolactone and ACE inhibitors was difficult to maintain, with high rates of discontinuation for one or both drugs.

Related Experiment Videos

  • Average starting dose of spironolactone was 55 mg, higher than in clinical trials.

    • Conclusions:

    • High rates of spironolactone discontinuation suggest challenges in long-term patient adherence.
    • Maintaining combination therapy with spironolactone and ACE inhibitors is difficult in practice.
    • Higher initial dosages may contribute to adverse effects and discontinuation.